BioAlliance, Innocutis sales and marketing update

BioAlliance granted Innocutis exclusive commercialization rights in North America for Sitavig acyclovir Lauriad. Sitavig is approved to treat recurrent orofacial herpes in the U.S. Innocutis, which expects to launch the product in 3Q14 for the dermatology market, said it will look to sublicense or partner the product for other specialty markets, including women's health and primary care. BioAlliance is eligible to receive up to $5 million in undisclosed upfront and milestone payments, plus double-digit royalties. Innocutis will also fund a "major portion" of the pediatric clinical study required by FDA and will be responsible for U.S. regulatory taxes. Innocutis said it will conduct the study in coordination with BioAlliance and expects the study to begin by 4Q14 or 1Q15.Locust Walk Partners advised BioAlliance. ...